Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)

NCT04197986 is registered in ClinicalTrials.gov with QED Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT04197986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04197986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Lead sponsor
QED Therapeutics, a BridgeBio company
Phase
Phase 3
Overall status
Terminated
Start date
March 11, 2020
Completion date
February 28, 2023
Enrollment
39 (actual)
Sites
143

Conditions

As the registry lists them; a condition with its own page is linked.

upper tract urothelial carcinomas, urothelial bladder cancer